「estimation」の検索結果

Set up, format, fix, and clean up LaTeX regression and estimation tables in empirical economics or finance papers. Use when (a) creating a .tex, results.tex, main.tex, or preamble to display regression or estimation output from Python (pyfixest), Stata, or R — including any mention of estout, esttab, estauto, estwide, or table fragments; (b) formatting or repairing estout-style regression tables that overflow the right margin, have cramped or boxed notes, misaligned columns, or poor significance stars, or when asked to match a reference paper, make the note fill the table width, or choose among \estwide, \estauto, and landscape layouts; (c) diagnosing "Misplaced \omit" errors from \input-ed table fragments inside tabular environments. Covers \@@input, \estwide, \estauto, \estautoLT, \specialcell, \sym, minipage notes below tabulars, and the convert-and-verify workflow. Do NOT trigger for general LaTeX documents like beamer presentations, problem sets, letters, or CVs.

日本語の概要は準備中です。原文の説明を表示しています。

Audit a mineral resource estimation system -- evaluate drillhole database integrity and QA/QC (CRMs, blanks, duplicates, umpire checks), geological and domain modeling quality, variogram analysis and grade interpolation methods (ordinary kriging, indicator kriging, IDW.

日本語の概要は準備中です。原文の説明を表示しています。

Audit a quoting or estimation system -- analyze labor hour estimation accuracy, material take-off completeness, pricing rule engines, markup and margin optimization, good-better-best tiered pricing, and quote-to-close win rates.

日本語の概要は準備中です。原文の説明を表示しています。

Pre-ticket Fibonacci sizing for a paste-mode batch of user stories. Default mode is advisory-only (writes a Story Sizing Report). Opt-in `--auto-create` delegates ticket creation to mk:jira-issue + mk:jira-collaborate with mandatory dry-run + single batch confirmation gate. NOT for single-ticket estimation (mk:jira-estimator); NOT for sprint capacity (mk:planning-engine).

日本語の概要は準備中です。原文の説明を表示しています。

Controls error rates across thousands of simultaneous tests in genomics discovery using false-discovery-rate methods (Benjamini-Hochberg 1995; Benjamini-Yekutieli 2001 for arbitrary dependence; Storey q-value with pi0 estimation; local FDR; independent filtering Bourgon 2010; covariate-weighted FDR via IHW Ignatiadis 2016), plus family-wise error control (Bonferroni, Holm) and the GWAS genome-wide threshold. Covers the FDR-versus-FWER choice as the discovery-versus-confirmatory distinction, the dependence assumptions behind BH (PRDS) versus BY, pi0 estimation, the independent-filtering and false-coverage-rate traps, and reproducibility ranking via IDR (Li 2011). Use when correcting p-values from genome-wide tests, choosing between BH/BY/q-value/Bonferroni, setting an FDR threshold, applying IHW or independent filtering, or interpreting q-values. For confirmatory trials with few pre-specified endpoints (closed testing, graphical/gatekeeping), see clinical-biostatistics/multiplicity-graphical.

日本語の概要は準備中です。原文の説明を表示しています。

Designs adaptive clinical trials including group-sequential (O'Brien-Fleming, Pocock, Lan-DeMets spending), sample-size re-estimation (blinded Friede-Kieser, unblinded Cui-Hung-Wang, Mehta-Pocock promising zone), seamless Phase 2/3 with treatment-arm selection, population enrichment, and response-adaptive randomisation. Covers FDA 2019 Final Adaptive Designs Guidance, FDA 2022 Master Protocols, and ICH E20 Step 2b/3 draft (June 2025, NOT final). Use when planning interim analyses, sample-size re-estimation, or master/platform-trial designs.

日本語の概要は準備中です。原文の説明を表示しています。

Expert-level computer vision for robotics covering camera models, feature detection, object detection, pose estimation, visual SLAM, and deep learning for perception.

日本語の概要は準備中です。原文の説明を表示しています。

Expert-level construction management covering project planning, scheduling, cost estimation, procurement, quality control, safety, and contract administration.

日本語の概要は準備中です。原文の説明を表示しています。

Use for Fermi estimation, or when a rough number is needed fast: "roughly how many...", "ballpark the cost", "estimate capacity or market size", "is this even feasible?". Decomposes, uses ranges and sanity-checks. Skip when exact data is available or a precise calculation is wanted.

日本語の概要は準備中です。原文の説明を表示しています。

Estimate AI-assisted and hybrid human+agent development work with research-backed PERT statistics and calibration feedback loops

日本語の概要は準備中です。原文の説明を表示しています。

Controls error rates across thousands of simultaneous tests in genomics discovery using false-discovery-rate methods (Benjamini-Hochberg 1995; Benjamini-Yekutieli 2001 for arbitrary dependence; Storey q-value with pi0 estimation; local FDR; independent filtering Bourgon 2010; covariate-weighted FDR via IHW Ignatiadis 2016), plus family-wise error control (Bonferroni, Holm) and the GWAS genome-wide threshold. Covers the FDR-versus-FWER choice as the discovery-versus-confirmatory distinction, the dependence assumptions behind BH (PRDS) versus BY, pi0 estimation, the independent-filtering and false-coverage-rate traps, and reproducibility ranking via IDR (Li 2011). Use when correcting p-values from genome-wide tests, choosing between BH/BY/q-value/Bonferroni, setting an FDR threshold, applying IHW or independent filtering, or interpreting q-values. For confirmatory trials with few pre-specified endpoints (closed testing, graphical/gatekeeping), see clinical-biostatistics/multiplicity-graphical.

日本語の概要は準備中です。原文の説明を表示しています。

Designs adaptive clinical trials including group-sequential (O'Brien-Fleming, Pocock, Lan-DeMets spending), sample-size re-estimation (blinded Friede-Kieser, unblinded Cui-Hung-Wang, Mehta-Pocock promising zone), seamless Phase 2/3 with treatment-arm selection, population enrichment, and response-adaptive randomisation. Covers FDA 2019 Final Adaptive Designs Guidance, FDA 2022 Master Protocols, and ICH E20 Step 2b/3 draft (June 2025, NOT final). Use when planning interim analyses, sample-size re-estimation, or master/platform-trial designs.

日本語の概要は準備中です。原文の説明を表示しています。

Decompose an unknown quantity into 3-5 estimable factors and produce a defensible order-of-magnitude answer without needing precise data. Load when the user needs to size something without data — market size, resource requirements, effort estimates, user numbers, costs — or when a decision is blocked by "we don't know the numbers". Also triggers on "ballpark this", "rough estimate", "how big is this market", "how long would this take", "how many users", or when deep-thinking diagnoses a sizing/estimation frame. The goal is not precision — it is a defensible answer that enables a decision to be made. Based on Enrico Fermi's estimation method.

日本語の概要は準備中です。原文の説明を表示しています。

Controls error rates across thousands of simultaneous tests in genomics discovery using false-discovery-rate methods (Benjamini-Hochberg 1995; Benjamini-Yekutieli 2001 for arbitrary dependence; Storey q-value with pi0 estimation; local FDR; independent filtering Bourgon 2010; covariate-weighted FDR via IHW Ignatiadis 2016), plus family-wise error control (Bonferroni, Holm) and the GWAS genome-wide threshold. Covers the FDR-versus-FWER choice as the discovery-versus-confirmatory distinction, the dependence assumptions behind BH (PRDS) versus BY, pi0 estimation, the independent-filtering and false-coverage-rate traps, and reproducibility ranking via IDR (Li 2011). Use when correcting p-values from genome-wide tests, choosing between BH/BY/q-value/Bonferroni, setting an FDR threshold, applying IHW or independent filtering, or interpreting q-values. For confirmatory trials with few pre-specified endpoints (closed testing, graphical/gatekeeping), see clinical-biostatistics/multiplicity-graphical.

日本語の概要は準備中です。原文の説明を表示しています。

Designs adaptive clinical trials including group-sequential (O'Brien-Fleming, Pocock, Lan-DeMets spending), sample-size re-estimation (blinded Friede-Kieser, unblinded Cui-Hung-Wang, Mehta-Pocock promising zone), seamless Phase 2/3 with treatment-arm selection, population enrichment, and response-adaptive randomisation. Covers FDA 2019 Final Adaptive Designs Guidance, FDA 2022 Master Protocols, and ICH E20 Step 2b/3 draft (June 2025, NOT final). Use when planning interim analyses, sample-size re-estimation, or master/platform-trial designs.

日本語の概要は準備中です。原文の説明を表示しています。

複数店舗の販売データや商品の特性をもとに、需要予測、安全在庫、発注量を検討するスキル。販促後の需要減少や季節商品の値下げ時期まで計画を支援します。

• 商品ごとの需要予測方法の選定
• 仕入れ先の納期変更に伴う安全在庫の見直し
• 販促中と終了後の需要を見積もりたいとき

Run RuView sensing applications — presence/occupancy, breathing & heart rate, activity & fall detection, 17-keypoint pose estimation (WiFlow), sleep monitoring & apnea screening, environment mapping, Mass Casualty Assessment (MAT), and the 3D point-cloud fusion demo. Use when someone wants to actually *do* something with a working RuView setup.

日本語の概要は準備中です。原文の説明を表示しています。

Supports multivariate severity assessment and exploratory endpoint-time score forecasting for laboratory animal studies using the RELSA (RELative Severity Assessment) score and ARIMA-based foRcast forecasting. Use when combining welfare readouts — body weight or weight loss, body temperature, clinical or nesting scores, biomarkers, activity, heart rate, burrowing, wheel running — into one severity score per animal per day, when asking which animals are at risk of reaching a humane endpoint at a specified future observation time, when defining attention/danger zones or thresholds on a severity scale by kernel density estimation, or when reporting severity for a 3Rs, refinement, animal-welfare, or EU Directive 2010/63/EU severity-assessment context. Covers directionality ("turned" variables), baseline normalization, reference sets, RELSA weights, ARIMA prediction intervals, and RMSE/PICP/MPIW evaluation.

日本語の概要は準備中です。原文の説明を表示しています。

Solves seawater carbonate chemistry with PyCO2SYS for chemical oceanography, ocean acidification, and marine carbon-cycle research. Use for paired total alkalinity, dissolved inorganic carbon, pH, or seawater pCO2/fCO2 measurements; carbonate speciation; aragonite and calcite saturation; Revelle factors; lab-to-in-situ temperature and pressure corrections; and measurement uncertainty propagation. Applies to carbonate-system calculations, not general aqueous speciation or air-sea gas-flux estimation.

日本語の概要は準備中です。原文の説明を表示しています。

Fetches real-time Azure retail pricing using the Azure Retail Prices API (prices.azure.com) and estimates Copilot Studio agent credit consumption. Use when the user asks about the cost of any Azure service, wants to compare SKU prices, needs pricing data for a cost estimate, mentions Azure pricing, Azure costs, Azure billing, or asks about Copilot Studio pricing, Copilot Credits, or agent usage estimation. Covers compute, storage, networking, databases, AI, Copilot Studio, and all other Azure service families.

日本語の概要は準備中です。原文の説明を表示しています。

Trade execution modeling (backtest only) — slippage formulas (linear / square-root impact), VWAP/TWAP execution logic, market-impact cost estimation, and execution-assumption configuration.

日本語の概要は準備中です。原文の説明を表示しています。

Scan codebases for technical debt, score severity, track trends, and generate prioritized remediation plans. Use when users mention tech debt, code quality, refactoring priority, debt scoring, cleanup sprints, or code health assessment. Also use for legacy code modernization planning and maintenance cost estimation.

日本語の概要は準備中です。原文の説明を表示しています。

Analyze and design pricing strategies including pricing models, competitive pricing analysis, willingness-to-pay estimation, and price elasticity. Use when setting prices, evaluating pricing models, preparing for a pricing change, or comparing freemium vs paid approaches.

日本語の概要は準備中です。原文の説明を表示しています。

Plan a sprint with capacity estimation, story selection, dependency mapping, and risk identification. Use when preparing for sprint planning, estimating team capacity, selecting stories, or balancing sprint scope against velocity.

日本語の概要は準備中です。原文の説明を表示しています。